PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC 2012 August 3.
Published in final edited form as:
PMCID: PMC3273849
NIHMSID: NIHMS342302

Natural variation in a chloride channel subunit confers avermectin resistance in C. elegans

Abstract

Resistance of nematodes to anthelmintics such as avermectins has emerged as a major global health and agricultural problem, but genes conferring natural resistance to avermectins are unknown. We show that a naturally occurring four amino-acid deletion in the ligand-binding domain of GLC-1, the alpha-subunit of a glutamate-gated chloride channel, confers resistance to avermectins in the model nematode Caenorhabditis elegans. We also find that the same variant confers resistance to the avermectin-producing bacterium Streptomyces avermitilis. Population-genetic analyses identified two highly divergent haplotypes at the glc-1 locus that have been maintained at intermediate frequencies by long-term balancing selection. These results implicate variation in glutamate-gated chloride channels in avermectin resistance and provide a mechanism by which such resistance can be maintained.

Avermectins are secondary metabolites of the cosmopolitan soil bacterium Streptomyces avermitilis(1) that are used for management of agricultural and parasitic nematode infestations. Abamectin (a mixture of avermectin B1a and B1b) is an agricultural pesticide, and ivermectin (a synthetic derivative of avermectin B1a and B1b) is a veterinary and human anthelmintic(2). Responses to avermectins by nematodes are thought to be dependent on a diverse set of molecules, including glutamate-gated chloride channels and P-glycoproteins(3). Widespread resistance of nematodes to these drugs is a global concern for agriculture and health(4), but the genetic basis of natural resistance to avermectins has remained elusive(4,5).

To investigate the genetic basis of natural avermectin resistance, we used a swimming assay(6) to quantify the ability of avermectins to induce paralysis(7) in strains of the nematode Caenorhabditis elegans isolated from different geographical locations. We found that a Hawaiian wild isolate of C. elegans, CB4856, was resistant to abamectin and ivermectin, while the laboratory strain, N2, was sensitive under identical conditions - e.g. exposure to 0.5 μg/ml of abamectin for thirty minutes resulted in paralysis of 98% of N2 worms but only 17% of CB4856 worms (Figs. 1A,B; S1A, S2). As a comparison, ivermectin reduces worm load by 100% in cattle infected with ivermectin-sensitive parasitic nematode Cooperia oncophora and by 70% in cattle infected with ivermectin-resistant C. oncophora(8). F1 heterozygotes from reciprocal crosses between N2 and CB4856 were as sensitive to abamectin as the N2 parent (Fig. 1A,B), suggesting that abamectin resistance may be a recessive trait caused by a loss-of-function allele in CB4856.

Figure 1
Sensitivity to abamectin differs between N2 and CB4856

To identify the gene(s) responsible for the observed difference in abamectin response, we carried out quantitative trait locus (QTL) mapping in a panel of recombinant inbred advanced intercross lines (RIAILs) generated from crosses between the N2 and CB4856 strains(9). We measured the frequency of body bends, as well as the probability of animals being paralyzed after 30 minutes in 0.5 μg/ml abamectin, for 210 RIAILs. The traits were not normally distributed, and were significantly correlated with each other (Fig. S3A). Nonparametric interval-mapping(10) for all measures of response to abamectin revealed a major QTL on chromosome V (Figs. 2A, S3B). RIAILs bearing the CB4856 allele at this locus exhibited higher mean frequency of body bends and lower probability of being paralyzed after 30 minutes of exposure to abamectin (Fig. 2C), but not all RIAILs with this allele were resistant, suggesting that additional loci are likely involved. Analysis of abamectin response as a binary trait(6) revealed a second QTL on chromosome III (Fig. S3C, D). Joint QTL analysis of the loci on chromosomes V and III indicated that they act additively and explain ~26% and ~6% of the phenotypic variance, respectively (6; Table S1).

Figure 2
Linkage analysis and fine mapping of the chromosome V locus

Genotyping of additional markers in RIAILs followed by transgenic rescue with fosmids identified an 11.4 kb segment of N2 DNA that abolished abamectin resistance in CB4856 (Figs. 2B,D,E,F,G, S5A–C). This region contained six genes, one of which, glc-1, encodes the alphasubunit of a glutamate-gated chloride channel(1113), a known target of avermectins(11,12). A 4.5 kb N2 genomic fragment containing two genes, including glc-1, significantly reduced abamectin resistance of CB4856 (Figs. 2F,G, S5D), supporting glc-1 as a candidate causal gene. Crossing CB4856 with the glc-1(pk54) mutant strain, which harbors a presumptive loss-offunction allele of glc-1 in the N2 background(12), resulted in F1 progeny resistant to abamectin, in contrast to F1 progeny from crosses between N2 and glc-1(pk54), which were sensitive (Fig. 3A). Introgression of the glc-1 region from N2 into CB4856 restored sensitivity to abamectin, whereas introgression of this region with the glc-1(pk54) mutation resulted in abamectin resistance comparable to CB4856 (Fig. 3A). These and additional results (6, Fig. S4) are consistent with a loss-of-function CB4856 allele of glc-1 conferring abamectin resistance in this genetic background(6).

Figure 3
Common naturally-occurring deletion in glc-1 confers abamectin resistance

To identify the underlying functional polymorphism(s), we sequenced the N2 and CB4856 alleles of glc-1. Relative to N2, CB4856 had 77 single nucleotide polymorphisms in the coding region, 32 of which resulted in amino-acid changes, as well as a four-amino-acid deletion in exon two (Fig. S6A). Despite the multiple coding polymorphisms, the predicted secondary structure and membrane topology of GLC-1 from N2 and CB4856 were similar (6, Fig. S6B,C). Alignment of the predicted structure of CB4856 GLC-1 with the three-dimensional structure(14) of homomeric GLC-1 bound to ivermectin and glutamate revealed no obvious changes in the overall structure of GLC-1 (Fig. S6C). Based on structure and annotation, we selected three candidate polymorphisms for further analysis. A threonine-to-alanine substitution at position 346 may weaken binding to avermectins by eliminating one of three hydrogen bonds between GLC-1 and ivermectin (Fig. S6C), an alanine-to-threonine change at position 20 may reduce the cleavage probability of the signal peptide(6) and a four amino-acid deletion in the ligand-binding domain of GLC-1 may interfere with the kinetics of glutamate binding. Comparison to the closest homolog of glc-1 in C. elegans, avr-15, showed that the CB4856 deletion allele is likely derived (Fig. S7A).

To test whether any of these polymorphisms confer resistance to abamectin in CB4856, we transformed CB4856 with N2 glc-1 cDNA constructs driven by a 1.1kb glc-1 promoter, separately harboring each of these three sequence changes observed in CB4856. The N2 glc-1 cDNA induced sensitivity to abamectin in the otherwise resistant CB4856 strain (Figs. 3B, S5I,J). Similar results were obtained when CB4856 worms were transformed with N2 glc-1 cDNA harboring the amino-acid substitutions in the signal peptide (A20T) or in the avermectin binding domain (T346A) (Figs. 3B, S5L,M,N). However, the construct harboring the deletion in the ligand-binding domain failed to induce sensitivity to abamectin in CB4856, demonstrating that the four-amino-acid deletion alone is sufficient to generate resistance to abamectin (Fig. 3B, S5K). We cannot rule out the possibility that other polymorphic residues also contribute to abamectin resistance.

A genome-wide association study measuring abamectin resistance in a diverse worldwide collection of 97 wild C. elegans isolates identified nine SNPs that were significantly associated (p < 3×10−7) with the fraction of worms paralyzed in abamectin (Fig. 3C). These SNPs all fell within a ~47 kb region of linkage disequilibrium that includes glc-1 (Fig. S9). We sequenced glc-1 in 53 diverse wild isolates and found that 16 carried CB4856-like alleles, including the four-amino-acid deletion, while 37 carried N2-like alleles lacking the deletion. As expected, the presence of the deletion was significantly associated (Pearson’s r=0.62, p < 0.0001) with abamectin resistance (Fig. S8). However, some isolates with the deletion were sensitive, and some isolates lacking it were resistant, indicating that other genetic factors influence abamectin response. We crossed six resistant wild isolates carrying CB4856-like glc-1 alleles to N2 and CB4856 and measured the abamectin response of the F1 cross-progeny (Fig. 3D). F1 progeny from crosses of MY10, JU258, EG4350, and MY19 to N2 were sensitive, while F1 progeny from crosses of these isolates to CB4856 were resistant, consistent with abamectin resistance in these strains also arising from loss of glc-1 function. However, F1 progeny from crosses of CX11307 and JU751 to both CB4856 and N2 were resistant, despite the same glc-1 sequence, suggesting the presence of a second, dominant resistance factor in these isolates (Fig. 3D). Taken together, these results imply that variation in glc-1 plays a major role in shaping abamectin resistance among C. elegans isolates, but the trait involves other loci.

The glc-1 region exhibited high sequence divergence between N2 and CB4856 (Fig. 4A), with 178 SNPs in ~5 kb, a polymorphism rate ~30-fold higher than the genome-wide average of one SNP per 840 bases(15). Sequences of five other glutamate-gated chloride channel subunit genes differed very little between N2 and CB4856 (Fig. S7B). Multiple lines of evidence suggested that the elevated level of polymorphism in glc-1 is due to long-term balancing selection, rather than an elevated mutation rate or population subdivision. Elevated sequence diversity is not consistent with relaxed constraint on one glc-1 allele, because the ratio of nonsynonymous to synonymous substitutions was 0.27, indicative of purifying selection (Table S2). The glc-1 sequences obtained from 53 wild isolates fall into two divergent clades (Fig. 4B). We observed 105 segregating sites among the isolates, but only six distinct haplotypes, fewer than expected for sequences evolving neutrally (P<0.0001; 6, Table S2). The SNPs in the region surrounding glc-1 were in complete linkage disequilibrium (Fig. S9). We also observed a significant positive Tajima’s D(16) (3.22; P<0.0001; Table S2), which is expected under balancing selection. Population subdivision is unlikely to explain these observations because both N2-like and CB4856-like haplotypes are observed globally, without any apparent geographic structure (Fig. S10). The extent of sequence divergence between the two haplotype clades was used to estimate that both haplotype classes have likely existed for 7.6 × 106 generations(6), which is older than typical coalescence times for neutral sequences in C. elegans. The observed molecular signatures in this region are analogous to the zeel-1/peel-1 region involved in a genetic incompatibility, where two ancient, highly diverged haplotype clades are also maintained by balancing selection(17).

Figure 4
glc-1 shows signatures of balancing selection and confers resistance to S. avermitilis

As avermectins are metabolites of S. avermitilis, a ubiquitous soil bacterium(1), exposure to S. avermitilis may represent a selective force for this balancing selection. S. avermitilis significantly reduced the brood size (Figs. 4C, S11) and induced uncoordinated movement in both CB4856 and N2. However, in the presence of S. avermitilis, the median brood size of CB4856 was approximately five-fold greater than that of N2. By contrast, in the absence of S. avermitilis, the median brood size of CB4856 was about half that of N2 (Fig. 4C). The strain with the glc-1 region from N2 introgressed into CB4856 showed a brood size reduction similar to N2 when exposed to S. avermitilis, while the introgression strain harboring the glc-1(pk54) mutation did not (Fig. 4C). These data are consistent with the hypothesis that a loss-of-function allele of glc-1 in the CB4856 background is responsible for generating resistance to S. avermitilis, most likely via its effect on avermectin resistance. Thus the CB4856 glc-1 allele may confer resistance to S. avermitilis but reduce fitness in the absence of this bacterium, perhaps due to pleiotropy of glc-1. glc-1 has been implicated in shaping the normal foraging pattern in N2(18) and is likely to form heteromeric channels with other glutamate-gated chloride channel subunits(2, 3, 19) that are critical for multiple physiological processes(3, 20). glc-1 is expressed in multiple tissues from the embryo through the adult stage, consistent with a role in diverse biological functions (Fig. S12).

Although diverse molecules have been identified as targets of avermectins(3), only a few studies have examined natural resistance, with glutamate-gated chloride channels implicated in some(21,22) but not others(23,24). We have identified a naturally occurring four amino-acid deletion in the ligand-binding domain of GLC-1 that plays a major role in avermectin resistance in the global C. elegans population. In the standard laboratory N2 strain, loss of function of three distinct glutamate-gated chloride channel subunits is required for resistance to avermectins as measured both by growth(13) and our swimming assay (Fig. S4). In contrast, we show that the loss of function of one channel subunit is sufficient for resistance in some wild isolates. The observed differences in resistance are modest compared to those in some species(25), suggesting that other mechanisms may be involved in generating greater resistance. The glc-1 variant that confers resistance to avermectins appears to be ancient and maintained by balancing selection, possibly due to a trade-off between resistance to common soil bacteria and a cost in their absence. Although we did not detect any obvious effect of this glc-1 variant on brood size in laboratory conditions in the absence of S. avermitilis, it is possible that in the wild, the effect of a glc-1 loss-of-function allele on multiple physiological processes may lead to lower fecundity or higher mortality. Analogous trade-offs have been observed for pathogen resistance genes in Arabidopsis(2628). Because many nematodes, including parasitic ones, spend part of their life cycle in soil, resistance to avermectins in the phylum may be common.

Supplementary Material

Supplementary Figures and Tables

Supplementary Legends

Supplementary Methods

Acknowledgments

We thank F. Albert, I. Ehrenreich, M. Rockman and H. Seidel for critical reading of the manuscript and members of the Kruglyak laboratory for suggestions; K. Chattopadhyay for advice regarding protein structure analysis and P. McGrath for sharing unpublished sequence information of the MY14 strain. Supported by a Merck fellowship of the Life Science Research Foundation (J.P.G.), NIH Ruth L. Kirschstein National Research Service Award (E.C.A.), James S. McDonnell Foundation Centennial Fellowship, Howard Hughes Medical Institute, NIH grants R01-HG004321 and R37- MH59520 (L.K.), and NIH grant P50- GM071508 to the Center for Quantitative Biology at the Lewis-Sigler Institute of Princeton University. Some of the C. elegans strains used were obtained from the Caenorhabditis Genetics Center. GenBank sequence accession numbers for the sequences are JN983734-JN983793.

References

1. Burg RW, et al. Antimicrob Agents Chemother. 1979 Mar;15:361. [PMC free article] [PubMed]
2. McCavera S, Walsh TK, Wolstenholme AJ. Parasitology. 2007;134:1111. [PubMed]
3. Wolstenholme AJ, Rogers AT. Parasitology. 2005;131(Suppl):S85. [PubMed]
4. Wolstenholme AJ, Fairweather I, Prichard R, von Samson-Himmelstjerna G, Sangster NC. Trends Parasitol. 2004 Oct;20:469. [PubMed]
5. Gilleard JS, Beech RN. Parasitology. 2007;134:1133. [PubMed]
7. Arena JP, et al. J Parasitol. 1995 Apr;81:286. [PubMed]
8. Njue AI, Prichard RK. Parasitol Res. 2004 Aug;93:419. [PubMed]
9. Rockman MV, Kruglyak L. PLoS Genet. 2009 Mar;5:e1000419. [PMC free article] [PubMed]
10. Kruglyak L, Lander ES. Genetics. 1995 Mar;139:1421. [PubMed]
11. Cully DF, et al. Nature. 1994 Oct 20;371:707. [PubMed]
12. Vassilatis DK, et al. J Biol Chem. 1997 Dec 26;272:33167. [PubMed]
13. Dent JA, Smith MM, Vassilatis DK, Avery L. Proc Natl Acad Sci U S A. 2000 Mar 14;97:2674. [PubMed]
14. Hibbs RE, Gouaux E. Nature. 2011 Jun 2;474:54. [PMC free article] [PubMed]
15. Wicks SR, Yeh RT, Gish WR, Waterston RH, Plasterk RH. Nat Genet. 2001 Jun;28:160. [PubMed]
16. Tajima F. Genetics. 1989 Nov;123(3):585. [PubMed]
17. Seidel HS, Rockman MV, Kruglyak L. Science. 2008 Feb 1;319:589. [PMC free article] [PubMed]
18. Cook A, et al. Mol Biochem Parasitol. 2006 May;147:118. [PubMed]
19. Etter A, Cully DF, Schaeffer JM, Liu KK, Arena JP. J Biol Chem. 1996 Jul 5;271:16035. [PubMed]
20. Dent JA, Davis MW, Avery L. EMBO J. 1997 Oct 1;16:5867. [PubMed]
21. Njue AI, Hayashi J, Kinne L, Feng XP, Prichard RK. J Neurochem. 2004 Jun;89:1137. [PubMed]
22. Kwon DH, Yoon KS, Clark JM, Lee SH. Insect Mol Biol. Aug;19:583. [PubMed]
23. El-Abdellati A, et al. Int J Parasitol. Aug 1;41:951. [PubMed]
24. McCavera S, Rogers AT, Yates DM, Woods DJ, Wolstenholme AJ. Mol Pharmacol. 2009 Jun;75:1347. [PubMed]
25. Kaplan RM, et al. Int J Parasitol. 2007 Jun;37:795. [PubMed]
26. Todesco M, et al. Nature. Jun 3;465465(7298):632. 632–6. [PMC free article] [PubMed]
27. Stahl EA, Dwyer G, Mauricio R, Kreitman M, Bergelson J. Nature. 1999 Aug 12;400:667. [PubMed]
28. Tian D, Traw MB, Chen JQ, Kreitman M, Bergelson J. Nature. 2003 May 1;423:74. [PubMed]